{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T02:14:53Z","timestamp":1760148893061,"version":"build-2065373602"},"reference-count":27,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2023,6,13]],"date-time":"2023-06-13T00:00:00Z","timestamp":1686614400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004895","name":"ESF","doi-asserted-by":"publisher","award":["POWR.03.02.00-00-I028\/17-00"],"award-info":[{"award-number":["POWR.03.02.00-00-I028\/17-00"]}],"id":[{"id":"10.13039\/501100004895","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of solid malignancies, including non-small-cell lung cancer. However, immunotherapy resistance constitutes a significant challenge. To investigate carbonic anhydrase IX (CAIX) as a driver of resistance, we built a differential equation model of tumor\u2013immune interactions. The model considers treatment with the small molecule CAIX inhibitor SLC-0111 in combination with ICIs. Numerical simulations showed that, given an efficient immune response, CAIX KO tumors tended toward tumor elimination in contrast to their CAIX-expressing counterparts, which stabilized close to the positive equilibrium. Importantly, we demonstrated that short-term combination therapy with a CAIX inhibitor and immunotherapy could shift the asymptotic behavior of the original model from stable disease to tumor eradication. Finally, we calibrated the model with data from murine experiments on CAIX suppression and combination therapy with anti-PD-1 and anti-CTLA-4. Concluding, we have developed a model that reproduces experimental findings and enables the investigation of combination therapies. Our model suggests that transient CAIX inhibition may induce tumor regression, given a sufficient immune infiltrate in the tumor, which can be boosted with ICIs.<\/jats:p>","DOI":"10.3390\/ijms241210068","type":"journal-article","created":{"date-parts":[[2023,6,14]],"date-time":"2023-06-14T01:32:15Z","timestamp":1686706335000},"page":"10068","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Carbonic Anhydrase IX Suppression Shifts Partial Response to Checkpoint Inhibitors into Complete Tumor Eradication: Model-Based Investigation"],"prefix":"10.3390","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4449-9846","authenticated-orcid":false,"given":"Julia","family":"Grajek","sequence":"first","affiliation":[{"name":"Nalecz Institute of Biocybernetics and Biomedical Engineering Polish Academy of Sciences, 02-109 Warsaw, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8758-7200","authenticated-orcid":false,"given":"Jan","family":"Poleszczuk","sequence":"additional","affiliation":[{"name":"Nalecz Institute of Biocybernetics and Biomedical Engineering Polish Academy of Sciences, 02-109 Warsaw, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2023,6,13]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, Activity, and Immune Correlates of Anti\u2013PD-1 Antibody in Cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"86","DOI":"10.3389\/fonc.2018.00086","article-title":"Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations","volume":"8","author":"Seidel","year":"2018","journal-title":"Front. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1146\/annurev-pathol-042020-042741","article-title":"Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance","volume":"16","author":"Bagchi","year":"2021","journal-title":"Annu. Rev. Pathol. Mech. Dis."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/s41416-020-0918-3","article-title":"Deciphering the response and resistance to immune-checkpoint inhibitors in lung cancer with artificial intelligence-based analysis: When PIONeeR meets QUANTIC","volume":"123","author":"Ciccolini","year":"2020","journal-title":"Br. J. Cancer"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/s41568-019-0116-x","article-title":"The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy","volume":"19","author":"Havel","year":"2019","journal-title":"Nat. Rev. Cancer"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1200\/JCO.2012.45.8703","article-title":"Harnessing the immune system for the treatment of non-small-cell lung cancer","volume":"31","author":"Brahmer","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1634\/theoncologist.2016-0189","article-title":"Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer","volume":"22","author":"Herzberg","year":"2017","journal-title":"Oncologist"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/nrc.2017.77","article-title":"Tumour acidosis: From the passenger to the driver\u2019s seat","volume":"17","author":"Corbet","year":"2017","journal-title":"Nat. Rev. Cancer"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1038\/s41416-018-0216-5","article-title":"Carbonic anhydrase IX is a pH-stat that sets an acidic tumour extracellular pH in vivo","volume":"119","author":"Lee","year":"2018","journal-title":"Br. J. Cancer"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1158\/0008-5472.CAN-08-2470","article-title":"Hypoxia-Inducible Carbonic Anhydrase IX and XII Promote Tumor Cell Growth by Counteracting Acidosis through the Regulation of the Intracellular pH","volume":"69","author":"Chiche","year":"2009","journal-title":"Cancer Res."},{"key":"ref_11","first-page":"7992","article-title":"Expression of Hypoxia-inducible Carbonic Anhydrase-9 Relates to Angiogenic Pathways and Independently to Poor Outcome in Non-Small Cell Lung Cancer","volume":"61","author":"Giatromanolaki","year":"2001","journal-title":"Cancer Res."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1038\/nrd3554","article-title":"Interfering with pH regulation in tumours as a therapeutic strategy","volume":"10","author":"Neri","year":"2011","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1097\/COC.0000000000000691","article-title":"A Phase 1 Study of SLC-0111, a Novel Inhibitor of Carbonic Anhydrase IX, in Patients with Advanced Solid Tumors","volume":"43","author":"McDonald","year":"2020","journal-title":"Am. J. Clin. Oncol. Cancer Clin. Trials"},{"doi-asserted-by":"crossref","unstructured":"De Campos, N.S.P., de Oliveira Beserra, A., Pereira, P.H.B., Chaves, A.S., Fonseca, F.L.A., da Silva Medina, T., dos Santos, T.G., Wang, Y., Marasco, W.A., and Suarez, E.R. (2022). Immune Checkpoint Blockade via PD-L1 Potentiates More CD28-Based than 4-1BB-Based Anti-Carbonic Anhydrase IX Chimeric Antigen Receptor T Cells. Int. J. Mol. Sci., 23.","key":"ref_14","DOI":"10.20944\/preprints202204.0308.v1"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"34341","DOI":"10.18632\/oncotarget.9114","article-title":"Chimeric antigen receptor T cells secreting anti-PD-L1 antibodies more effectively regress renal cell carcinoma in a humanized mouse model","volume":"7","author":"Suarez","year":"2016","journal-title":"Oncotarget"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1158\/2326-6066.CIR-18-0657","article-title":"Targeting Hypoxia-Induced Carbonic Anhydrase IX Enhances Immune-Checkpoint Blockade Locally and Systemically","volume":"7","author":"Chafe","year":"2019","journal-title":"Cancer Immunol. Res."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"20220654","DOI":"10.1098\/rsif.2022.0654","article-title":"An in silico model to study the impact of carbonic anhydrase IX expression on tumour growth and anti-PD-1 therapy","volume":"20","author":"Grajek","year":"2023","journal-title":"J. R. Soc. Interface"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1093\/nsr\/nwx062","article-title":"The acidic tumor microenvironment: A target for smart cancer nano-theranostics","volume":"5","author":"Feng","year":"2018","journal-title":"Natl. Sci. Rev."},{"doi-asserted-by":"crossref","unstructured":"Cortes-Dericks, L., and Galetta, D. (2022). Impact of Cancer Stem Cells and Cancer Stem Cell-Driven Drug Resiliency in Lung Tumor: Options in Sight. Cancers, 14.","key":"ref_19","DOI":"10.3390\/cancers14020267"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"5210","DOI":"10.1038\/onc.2012.550","article-title":"Targeting carbonic anhydrase IX depletes breast cancer stem cells within the hypoxic niche","volume":"32","author":"Lock","year":"2012","journal-title":"Oncogene"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.compchemeng.2012.06.001","article-title":"Advances and selected recent developments in state and parameter estimation","volume":"51","author":"Kravaris","year":"2013","journal-title":"Comput. Chem. Eng."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/7651_2016_346","article-title":"Agent-Based Modeling of Cancer Stem Cell Driven Solid Tumor Growth","volume":"1516","author":"Poleszczuk","year":"2016","journal-title":"Methods Mol. Biol."},{"doi-asserted-by":"crossref","unstructured":"Poleszczuk, J., and Enderling, H. (2018). The Optimal Radiation Dose to Induce Robust Systemic Anti-Tumor Immunity. Int. J. Mol. Sci., 19.","key":"ref_23","DOI":"10.20944\/preprints201809.0230.v1"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/BF02460644","article-title":"Nonlinear dynamics of immunogenic tumors: Parameter estimation and global bifurcation analysis","volume":"56","author":"Kuznetsov","year":"1994","journal-title":"Bull. Math. Biol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"025017","DOI":"10.1088\/1361-6560\/aaf96c","article-title":"Predicting tumour response to anti-PD-1 immunotherapy with computational modelling","volume":"64","author":"Valentinuzzi","year":"2019","journal-title":"Phys. Med. Biol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1097\/PPO.0000000000000301","article-title":"PD-L1 and Emerging Biomarkers in PD-1\/PD-L1 Blockade Therapy","volume":"24","author":"Cottrell","year":"2018","journal-title":"Cancer J."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/1475-2867-13-75","article-title":"A characterization of four B16 murine melanoma cell sublines molecular fingerprint and proliferation behavior","volume":"13","author":"Danciu","year":"2013","journal-title":"Cancer Cell Int."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/12\/10068\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:54:01Z","timestamp":1760126041000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/12\/10068"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,13]]},"references-count":27,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2023,6]]}},"alternative-id":["ijms241210068"],"URL":"https:\/\/doi.org\/10.3390\/ijms241210068","relation":{},"ISSN":["1422-0067"],"issn-type":[{"type":"electronic","value":"1422-0067"}],"subject":[],"published":{"date-parts":[[2023,6,13]]}}}